Date:5/5/2009

agraphs, many of which are outside the control of the Company. These uncertainties and other factors include the uncertainty of market acceptance of any potential service offerings relating to types of stem cells other than cord blood stem cells, including the Celle service, given that menstrual stem cells and other new stem cells have not yet been used in human therapies, and treatment applications using such stem cells are not likely to be developed and commercialized for many years and are subject to further research and development; the need for additional development and testing before determining the ultimate commercial value of the Company's intellectual property relating to the menstrual stem cells; the need to complete certain developments, including completion of clinical validation and testing, before any new process other than Celle can be commercialized, and the Company's development of its final business and economic model in offering any such service; any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company's business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any co
'/>"/>

SOURCE Cryo-Cell International, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Xanodynes New Drug Application for the Treatment of Heavy Menstrual Bleeding (Menorrhagia) Accepted for Filing with a Priority Review Classification
2. Menstrual Bleeding Treatment Safer Than Thought
3. Mayo researchers offer new insight into effectiveness of procedure to stop heavy menstrual bleeding
4. Taking Control: Future Therapies for a Host of Serious Diseases May Be Found in Womens Menstrual Blood
5. Complementary medicines can help mild depression and premenstrual syndrome
6. Delayed Sleep Pattern Tied to Irregular Menstrual Cycles
7. Safe to Stop the Flow?: Differing Attitudes Found Between Women and Doctors Concerning Menstrual Suppression
8. Differing attitudes found between women and doctors concerning menstrual suppression
9. Weizmann Institute scientists show white blood cells move like millipedes
10. Healthy Living Network Announces Launch of New Blood Sugar Web Site
11. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill